PURPOSE: In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response. PATIENTS AND METHODS: Tumor colon samples from 21 patients with advanced colorectal cancer were analyzed for gene expression profiling using Human Genome GeneChip arrays U133. At the end of the first-line treatment, the best observed response, according to WHO criteria, was used to define the responders and nonresponders. Discriminatory genes were first selected by the significance analysis of microarrays algorithm and the area under the receiver operating characteristic curve. A predictor classifier was then constructed using support vector machines. Finally, leave-one-out cross validation was used to estimate the performance and the accuracy of the output class prediction rule. RESULTS: We determined a set of 14 predictor genes of response to FOLFIRI. Nine of nine responders (100% specificity) and 11 of 12 nonresponders (92% sensitivity) were classified correctly, for an overall accuracy of 95%. CONCLUSION: After validation in an independent cohort of patients, our gene signature could be used as a decision tool to assist oncologists in selecting colorectal cancer patients who could benefit from FOLFIRI chemotherapy, both in the adjuvant and the first-line metastatic setting.
PURPOSE: In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response. PATIENTS AND METHODS: Tumor colon samples from 21 patients with advanced colorectal cancer were analyzed for gene expression profiling using Human Genome GeneChip arrays U133. At the end of the first-line treatment, the best observed response, according to WHO criteria, was used to define the responders and nonresponders. Discriminatory genes were first selected by the significance analysis of microarrays algorithm and the area under the receiver operating characteristic curve. A predictor classifier was then constructed using support vector machines. Finally, leave-one-out cross validation was used to estimate the performance and the accuracy of the output class prediction rule. RESULTS: We determined a set of 14 predictor genes of response to FOLFIRI. Nine of nine responders (100% specificity) and 11 of 12 nonresponders (92% sensitivity) were classified correctly, for an overall accuracy of 95%. CONCLUSION: After validation in an independent cohort of patients, our gene signature could be used as a decision tool to assist oncologists in selecting colorectal cancerpatients who could benefit from FOLFIRI chemotherapy, both in the adjuvant and the first-line metastatic setting.
Authors: M P Brown; W N Grundy; D Lin; N Cristianini; C W Sugnet; T S Furey; M Ares; D Haussler Journal: Proc Natl Acad Sci U S A Date: 2000-01-04 Impact factor: 11.205
Authors: Virginie Copois; Frédéric Bibeau; Caroline Bascoul-Mollevi; Nicolas Salvetat; Patrick Chalbos; Corinne Bareil; Laurent Candeil; Caroline Fraslon; Emmanuel Conseiller; Virginie Granci; Pierre Mazière; Andrew Kramar; Marc Ychou; Bernard Pau; Pierre Martineau; Franck Molina; Maguy Del Rio Journal: J Biotechnol Date: 2006-08-02 Impact factor: 3.307
Authors: D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531
Authors: Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz Journal: J Clin Oncol Date: 2001-12-01 Impact factor: 44.544
Authors: Oghenekevwe M Gbenedio; Caroline Bonnans; Delphine Grun; Chih-Yang Wang; Ace J Hatch; Michelle R Mahoney; David Barras; Mary Matli; Yi Miao; K Christopher Garcia; Sabine Tejpar; Mauro Delorenzi; Alan P Venook; Andrew B Nixon; Robert S Warren; Jeroen P Roose; Philippe Depeille Journal: JCI Insight Date: 2019-06-25
Authors: Katherine S Garman; Chaitanya R Acharya; Elena Edelman; Marian Grade; Jochen Gaedcke; Shivani Sud; William Barry; Anna Mae Diehl; Dawn Provenzale; Geoffrey S Ginsburg; B Michael Ghadimi; Thomas Ried; Joseph R Nevins; Sayan Mukherjee; David Hsu; Anil Potti Journal: Proc Natl Acad Sci U S A Date: 2008-12-02 Impact factor: 11.205
Authors: Sandra Van Schaeybroeck; Wendy L Allen; Richard C Turkington; Patrick G Johnston Journal: Nat Rev Clin Oncol Date: 2011-02-15 Impact factor: 66.675
Authors: Anguraj Sadanandam; Costas A Lyssiotis; Krisztian Homicsko; Eric A Collisson; William J Gibb; Stephan Wullschleger; Liliane C Gonzalez Ostos; William A Lannon; Carsten Grotzinger; Maguy Del Rio; Benoit Lhermitte; Adam B Olshen; Bertram Wiedenmann; Lewis C Cantley; Joe W Gray; Douglas Hanahan Journal: Nat Med Date: 2013-04-14 Impact factor: 53.440